News & Events

Disc Medicine to Present at Citi's 15th Annual BioPharma Virtual Conference

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will present at Citi’s 15th Annual BioPharma Virtual Conference today, Tuesday, September 8, 2020 at 2:20pm ET.

About Disc Medicine

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

 

Media Contact:

Arleen Goldenberg

Verge Scientific Communications

202.930.4762

More News

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million...


read more

Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including...


read more

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Alignment with the FDA across all proposed study parameters, providing a clear development path to registration Agreement on proposed primary endpoint of...


read more